Clinical trialPhase 2Completed
Immune Checkpoint Inhibition in Combination With Radiation Therapy in Pancreatic Cancer or Biliary Tract Cancer Patients
A Prospective Randomized, Open-label Phase 2 Study of Immune Checkpoint Inhibition, Nivolumab With or Without Ipilimumab in Combination With Radiation Therapy in Pretreated Patients With Metastatic Pancreatic Cancer or Biliary Tract Cancer.
- Outcome
- Finished, no results posted
- Phase
- Phase 2
- Status
- Completed
- Study type
- Interventional
- Start
- November 2016
- Expected end
- 30 November 2022
- Enrollment
- 160 participants
- Sites
- 1
- Primary outcomes
- Clinical benefit rate (CBR)
- Sponsor
- Other
- Results posted
- No
- Last update
- 22 September 2023
These are registry fields. A trial card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess. Only its metadata is loaded so far, so most questions will be declined.
Try
Papers 3
- Builds on itImpact of Liver Metastases on Outcomes With Chemotherapy or Immune Checkpoint Inhibitors in Pancreatic Cancer. DOI 10.1002/iid3.70545↗
- Builds on itPlasma YKL-40 is associated with prognosis in patients with metastatic pancreatic cancer receiving immune checkpoint in… DOI 10.3389/fimmu.2023.1228907↗
- Builds on itRandomized Phase II Study of Nivolumab With or Without Ipilimumab Combined With Stereotactic Body Radiotherapy for Refr… DOI 10.1200/jco.21.02511↗